Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus XELOX versus short-course radiotherapy followed by XELOX for neoadjuvant treatment of middle and low rectal cancer
ChiCTR2600131516Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal adenocarcinoma (2 arms), sponsored by Xijing Hospital. Primary endpoint: Pathological complete response rate. Started May 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600131516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131516.